What Is HGH Fragment 176-191?

1. HGH Fragment 176-191 vs AOD-9604

The human growth hormone sequence in UniProt ends in FLRIVQCRSVEGSCGF. In standard amino-acid notation, F means phenylalanine. The numbers 176–191 refer to positions in the mature hormone, after its signal peptide has been removed.

Cox and colleagues describe AOD-9604 as hGH 177–191 with tyrosine added at the beginning. Tyrosine is Y. Compared with native hGH 176–191, this replaces the initial F with Y; both peptides contain 16 amino acids. AOD-9604 also has a defined disulfide bond connecting its two cysteine residues.

Commercial naming does not always preserve that distinction. A product labeled “HGH fragment” may be described using AOD-9604’s sequence or references. Before accepting a result, match the molecule, formulation and route in the paper to the claim. The name on a vial alone cannot establish that match.

The AOD-9604 guide covers its obesity-development program in detail. Here, those studies provide related evidence, with their identity kept explicit.

2. How is HGH frag supposed to work?

Researchers investigated growth hormone’s C-terminal region, the end of its amino-acid chain, for effects on fat metabolism. The development rationale was to retain some metabolic activity while avoiding the full hormone’s growth-promoting effects. Moré and Kenley describe this work.

Three processes often get compressed into the phrase “fat burning.” Lipolysis releases fatty acids from stored fat. Fat oxidation uses fatty acids for energy. Losing body fat means the amount stored declines over time. Measuring the first process alone does not tell you how much body fat someone will lose.

In Heffernan et al.’s mouse experiments, AOD-9604 reduced body weight and fat after 14 days and increased expression of beta-3 adrenergic receptors, which participate in fat metabolism. The researchers concluded that its lipolytic action was not mediated directly through those receptors. Describing HGH frag as a proven selective beta-3 agonist goes beyond that evidence twice: it assigns a mechanism the paper did not establish, then transfers it to another peptide.

3. What do the studies show?

The papers below answer different questions. Only the first directly tests native hGH 176–191 among several defined GH fragments; the AOD-9604 studies concern the modified peptide.

The rat result is sometimes described as “over 50%” less weight gain. That comparison is mathematically reasonable, but calling it a 50% reduction in body fat changes the outcome. It also changes the subject when attributed to native HGH Fragment 176–191.

There is a newer paper with “Human Growth Hormone Fragment 176-191” in its title. Habibullah et al. (2022) tested a peptide-containing nanoparticle formulation with doxorubicin against breast cancer cells. It provides neither a human fat-loss result nor evidence that injecting the fragment prevents or treats cancer.

4. Does HGH Fragment 176-191 work for fat loss?

The reviewed literature does not establish how many kilograms of fat a person can expect to lose from the native fragment. The larger human experiment often brought into this discussion tested oral AOD-9604.

According to the FDA’s review of the OPTIONS study, 502 adults with obesity were randomized to AOD-9604 or placebo alongside diet and exercise. Weight loss did not differ significantly from placebo at 12 or 24 weeks. This failed result needs to accompany the early animal findings whenever the related compound is used to support a fat-loss claim.

The oral trial does not prove that every possible injected fragment is ineffective. It also supplies no evidence that changing to injections solves the problem. That proposition requires a trial of the specified injectable product.

For belly fat, the missing measurement is more specific still. Fat beneath the skin and visceral fat around the organs are different compartments. No controlled human result identified here establishes selective loss of either with native HGH frag, or shows that injecting near a fat deposit makes that area shrink.

5. Dosage, half-life and fasted cardio

No validated human fat-loss dose, injection frequency or cycle length follows from these studies. Historical oral AOD-9604 doses cannot become an HGH fragment injection protocol through a milligram-to-microgram conversion.

The often-repeated approximately three-minute half-life comes from intravenous AOD-9604 in pigs. It describes that peptide, species and route. A reliable human subcutaneous half-life for native HGH Fragment 176–191 was not established in the literature reviewed here.

Fasted-cardio schedules add another assumption. A plausible explanation about mobilizing fat does not identify how long to fast, when to inject or whether the combination reduces body fat more than the same training and food intake without the peptide. The cited experiments did not resolve those questions.

For anyone evaluating a protocol posted online, look for the actual human experiment behind its timing. A graph generated from an assumed half-life repeats the assumption; it does not measure absorption or validate the schedule.

6. Side effects, blood sugar and IGF-1

“No effect on blood sugar” is too broad for native HGH Fragment 176–191. In the 1978 Ng and Bornstein experiment, the active fragments, including 176–191, caused a brief glucose rise, a longer insulin rise and reduced insulin sensitivity. These rat findings cannot determine the frequency or severity of glucose problems in people. They do give a concrete reason to question a guarantee of glucose neutrality.

The later AOD-9604 human safety analysis reported different findings under different conditions. It did not find significant IGF-1 increases or impaired glucose tolerance. Two authors had Metabolic Pharmaceuticals affiliations, and the paper summarized the development program rather than independent replication.

There is no dependable human adverse-event rate for repeated native-fragment injections in the evidence reviewed here. Similarly, a normal IGF-1 result cannot establish long-term cancer safety or exclude other adverse effects.

Product quality introduces separate uncertainty. FDA flags immune-reaction risks, peptide impurities and inadequate safety information for compounded AOD-9604. That warning concerns AOD-9604; it does not quantify native-fragment risk. For an injectable product, identity, sterility, endotoxins and amount per vial are separate questions. A purity percentage alone answers too few of them.

7. HGH frag vs HGH, tesamorelin and peptide stacks

Removing most of a hormone’s sequence does not establish that the resulting fragment preserves its desired effects. Full-length HGH, GH-releasing peptides and HGH fragments need separate evidence.

The tesamorelin prescribing information also states that it is not indicated for weight-loss management. Its medical indication cannot be extended to every person seeking a smaller waist.

Starting a fragment while changing calories, training and another drug makes a before-and-after result difficult to attribute. Keeping strength during a cut is worth recording, but it cannot establish that the fragment preserved muscle. The comparison would need to separate its contribution from training, nutrition and the other treatment.

8. Tested sport and interpreting your own records

WADA’s 2026 Prohibited List explicitly names both hGH 176–191 and AOD-9604 under S2.2.3. Both are prohibited in and out of competition. A short reported half-life is not an anti-doping clearance window: Cox et al. found an AOD-9604 breakdown product that persisted longer than the parent peptide in laboratory samples.

If you are reviewing past or current use with a clinician, record the exact product name and stated sequence, other compounds, symptoms and dated laboratory results. Add calorie and training changes alongside weight and waist measurements. A tracking record can preserve those details, but cannot verify a vial or replace a controlled comparison. Record a change in waist size as a waist measurement; keep any claim about what caused it separate.

9. HGH Fragment 176-191 FAQ

• What is HGH Fragment 176-191 used for?

  It is marketed for fat loss and physique cutting. It is a synthetic version of a short segment of growth hormone, but controlled human evidence has not established a dependable fat-loss benefit for the native fragment.

• Is HGH Fragment 176-191 the same as AOD-9604?

  Their defined sequences differ at the first amino acid: phenylalanine in native hGH 176-191, tyrosine in AOD-9604. Product names are used inconsistently, so the sequence and formulation need checking before assigning a paper's results to a product.

• Does HGH Fragment 176-191 burn belly fat?

  The studies reviewed here do not establish selective loss of belly fat or love handles in humans. A smaller waist during dieting cannot identify how much, if anything, a fragment added.

• How long does HGH Fragment 176-191 take to work?

  There is no validated timeline for visible fat loss. Animal experiments and AOD-9604 trial endpoints cannot predict when a person using an HGH fragment product will see results.

• What is the HGH Fragment 176-191 dosage?

  No evidence-based human fat-loss dose or cycle is established for the native fragment. AOD-9604 oral trial doses and animal doses cannot supply a subcutaneous HGH fragment protocol.

• Should HGH frag be taken before fasted cardio?

  The reviewed studies do not establish a fasting interval or show that pairing the native fragment with fasted cardio produces more sustained fat loss. An explanation about fat mobilization cannot determine an effective schedule.

• Does HGH Fragment 176-191 raise blood sugar or IGF-1?

  Direct rat research found glucose and insulin effects from the native fragment. AOD-9604 human studies reported no significant IGF-1 increase or deterioration in glucose tolerance. These are different molecules and experiments; neither supplies a dependable safety forecast for a research vial.

• What is HGH Fragment 176-191's half-life?

  A reliable human subcutaneous half-life was not established in the research reviewed here. The approximately three-minute figure in a related paper came from intravenous AOD-9604 in pigs.

• Can you stack HGH Fragment 176-191 with tirzepatide or CJC-1295?

  The reviewed evidence does not establish additional fat loss, muscle preservation or safety from these combinations. Starting multiple compounds together also makes their individual contributions difficult to identify.

• Is HGH Fragment 176-191 banned in sport?

  Yes. WADA's 2026 Prohibited List explicitly names hGH 176-191 and AOD-9604 under S2.2.3. Both are prohibited in and out of competition.

10. Sources